Several studies have determined the efficacy of angiotensin-receptor blockers (ARBs) for treating heart failure. However, the relationship between high and low doses and clinical outcomes has been poorly studied to date. […]
Category: General cardiology
Ventilation strategies in cardiac arrest
Long-term survival for adult out-of-hospital cardiac arrest victims remains dismal and is typically less than 10%. Historically, many resuscitation guidelines have had little evidence to support their recommendations but research in this field has been burgeoning, with advanced life support guidelines undergoing substantial recent changes to reflect new findings. One of these changes has been […]
Dual antiplatelet therapy may be beneficial post-CABG
Perioperative aspirin therapy in CABG improves graft patency, prevents ischemic events, and prolongs survival. However, Aspirin resistance is common after CABG, particularly in the immediate post-operative period, in part due to cardiopulmonary bypass causing a pro-inflammatory, pro-thrombotic state. Clopidogrel has revolutionised the practice of interventional cardiology but it remains unknown whether more aggressive antiplatelet treatment […]
Cardiac Outcomes in Childhood Cancer Survivors
Therapeutic advances in paediatric oncology have led to an increase in the number of adult survivors of childhood cancers. However, it is not currently known whether their long term health is influenced by the cancer therapies they receive. […]
Niacin HALTS progression of carotid thickness in imaging trial
Due to the residual risk that remains with statin monotherapy, cholesterol treatment can be intensified with the use of a secondary agent such a ezetimibe or nicotinic acid. Whist ezetimibe has potent LDL-lowering capabilities, nicotinic acid is also capable of raising HDL-cholesterol and lowering triglyceride levels. […]
Cardiovascular Outcomes in Diabetics Complicated by Comorbidities
Many trials over the last decade have suggested little cardiovascular benefit from treating diabetics to aggressive HbA1c levels of 6.5-7.0%. However, post hoc analyses and other meta-analyses have suggested that a benefit may still be possible if treatment is started before diabetes has become well established. […]
Increased use of antithrombotics increases hospital admissions for bleeding
The safety of multiple antithrombotic drug regimes has not been investigated in clinical trials. Specifically, guidelines for the management of patients with myocardial infarction who also have an indication for warfarin are currently unclear; some recommend the use of clopidogrel and warfarin in combination following coronary stent implantation. As bleeding episodes following myocardial infarction are […]
ACE and ARB in combination give no added benefits
Both angiotensin-converting enzyme (ACE) inhibitors and angiotensin II-receptor blockers (ARBs) have been shown to be of benefit in patients with heart failure, and in patients who have reduced ventricular function following a myocardial infarction. However, it is less well known whether they provide benefit in patients with ischaemic heart disease (IHD) and preserved ventricular function. […]
Novel blood pressure lowering agent shows promise in resistant hypertension
Novel blood pressure lowering agent shows promise in resistant hypertension Darusentan is a novel endothelin antagonist designed for the treatment of hypertension; raised levels of endothelin 1 have been reported both in patients with hypertension and those with diabetes. […]
Paclitaxel Stents Safe in STEMI
The Harmonising Outcomes with Revascularisation and Stents in Acute Myocardial Infarction (HORIZONS-AMI) was a prospective open label, multi-centre controlled trial involving patients with ST-elevation myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention (PPCI). It incorporated two factorial randomised phases to allow a comparison of the direct thrombin inhibitor bivalirudin alone with heparin plus glycoprotein IIb-IIIa […]